Results 121 to 130 of about 8,127 (167)

Real-world efficacy and safety of CDK4/6 inhibitors plus endocrine therapy in HR+/HER2 - metastatic breast cancer: a single-institution experience. [PDF]

J Egypt Natl Canc Inst
Hussein NE, Gad AM, AbdAllah A, El Baghdady NS.   +3 more
europepmc   +1 more source

Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2- metastatic breast cancer. [PDF]

Oncologist
Brufsky A, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, Estevez M, Cottu P, Thill M, Curigliano G, Rugo HS.   +11 more
europepmc   +1 more source

Mitigating Severe Ribociclib-Hepatotoxicity With Corticosteroids. [PDF]

Case Rep Oncol Med
Williamson J, Pletneva M, Kim RG, Bhatia R.   +3 more
europepmc   +1 more source

Real-World Data on the Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer. [PDF]

World J Oncol
Savvidou Α, Constantinidou A, Zacharia L, Michailidou K, Zanti Μ, Kitiri S, Marcou Y, Konstantinou I, Kakouri E, Galazi M, Petrou C.   +10 more
europepmc   +1 more source

Drug-Induced Pneumonitis Secondary to Ribociclib in a Patient With Metastatic Breast Cancer. [PDF]

Cureus
Mustafa Z, Ahmad M, Alkhatib M, Haq IU, Allangawi M, Thomas M, Hameed M.   +6 more
europepmc   +1 more source

Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo. [PDF]

Cancer Chemother Pharmacol
Drabison T, Ahmed EA, Colasanti N, Weber RH, Sparreboom A, Eisenmann ED.   +5 more
europepmc   +1 more source

Clinical features and management for CDK4/6 inhibitor-DILI. [PDF]

JHEP Rep
Riveiro-Barciela M, Esteban P, Vega-Cano KS, Mateos B, Miranda EL, Jara P, Martín M, Alonso López S, Salcedo M, Forns X, García-Fructuoso I, Martínez-Sáez O, Pinazo-Bandera J, García-Cortés M, Ribelles N, Romanos Nanclares Á, Morchón-Araujo D, Rodríguez CA, Lozano R, Domínguez-Gómez R, Cejuela M, Torres-Sempere J, Ruiz-Cobo JC, Villagrasa A, Zamora E, Buti M, Bellet M.   +26 more
europepmc   +1 more source

Real-world progression-free survival 2 (PFS2) and tumor response of CDK4/6 inhibitors plus an aromatase inhibitor in patients with HR+/HER2- metastatic breast cancer in US routine clinical practice. [PDF]

Breast
Rugo HS, Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Lynce F, Cottu P, Thill M, Curigliano G.   +11 more
europepmc   +1 more source

Clinical Applications of CDK4/6 Inhibitors in HR+/HER2, and Personalized Treatment Strategies: A Narrative Review. [PDF]

Oncol Res
Zhong G, Yang T, Lin S, Zhong M.
europepmc   +1 more source

Real-world progression-free survival and overall survival in patients with HR⁺/HER2^- advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study. [PDF]

Int J Cancer
Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lüdtke-Heckenkamp K, Lüftner D, Marmé F, van Mackelenbergh M, Rautenberg B, Schmidt M, Weide R, Wimberger P, Kisseleff E, Pfister C, Quiering C, Roos C, Wöckel A.   +20 more
europepmc   +1 more source